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Abstract
The Herpes simplex virus (HSV) is known as an infectious agent and widespread in the human
population. The symptoms of HSV infections can range from mild to life threatening, especially in
immune-compromised individuals. HSV infections are commonly treated with the guanosine
analogue Aciclovir, but reports of resistance are increasing. Efforts are made to establish single-
stranded antisense oligodeoxynucleotides (as) and small interfering ribonucleic acids (siRNAs) for
antiviral treatment. Recently, another class of short interfering nucleic acids, partially double-
stranded hairpin loop-structured 54 mer oligodeoxynucleotides (ODNs), was shown to allow
hydrolysis of HIV RNA by binding to the viral RNA. This leads to a substrate for the viral RNase
H. To assess the potential of such ODNs for inhibition of HSV-1 replication, five partially double-
stranded ODNs were designed based on the sequences of known siRNAs against HSV-1 with
antiviral activity. Three of them are directed against early and two against leaky late genes. Primary
human lung fibroblasts, MRC-5, and African green monkey kidney cells, Vero, were transfected
with ODNs and subsequently infected. The effect on HSV-1 replication was determined by
analyzing the virus titer in cell culture supernatants by quantitative PCR and plaque assays. An
inhibitory effect was observed with all five selected ODNs, with two cases showing statistical
significance in both cell types. The observed effect was sequence-specific and dose dependent. In
one case the ODN was more efficient than a previously described siRNA directed against the same
target site in the mRNA of UL5, a component of the helicase/primase complex. HSV-1 virions and
ODNs can be applied simultaneously without transfection reagent, but at a 50-fold higher
concentration to Vero cells with similar efficiencies. The results underline the potential of partially
double-stranded hairpin loop-structured ODNs as antiviral agents.
Findings
The Herpes simplex virus (HSV), a member of the family
Herpesviridae, is a large DNA virus with a high prevalence
in the human population. HSV genes are expressed in a
highly regulated cascade during productive infection [1].
They are grouped in immediate early (IE), early (E), leaky-
late (LL) and late genes (L) according to the time point of
expression after infection (figure 1A). In this study, we are
targeting four essential HSV-1 genes with a new class of
oligodeoxynucleotides, partially double-stranded hairpin
loop-structured 54 mer ODNs. The ODNs consist of a 25
mer antisense strand fully complementary to the target
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Model for ODN-mediated inhibition of HSV-1 and ODNs used Figure 1
Model for ODN-mediated inhibition of HSV-1 and ODNs used. A. The HSV expression cascade during replication 
consists of the expression of (1) immediate early genes (IE) and (2) early (E) genes from the circularized HSV genome, of (3) 
leaky late genes (LL) from the parental genome and progeny genomes and of (4) late genes (L) from progeny genomes. ODNs 
target mRNAs of early and leaky late gene products, a component of the helicase/primase complex, the single strand binding 
protein (SBB), the polymerase as well as the tegument protein VP16, which is a component of the virion and facilitates IE gene 
expression in the next round of infection. B. Target sites (bold) and sequences of the oligonucleotides used. C. ODN A, S2, Sc, 
Cont and asS2 served as negative controls.
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mRNA site, a linker of four thymidines, and a 25 mer sec-
ond strand partially complementary to the antisense
strand. ODNs with the same structure proved their capa-
bility to mediate hydrolysis of HIV-1 RNA by HIV-1
reverse transcriptase (RT)-associated RNase H in HIV viri-
ons and patient-derived plasma in a sequence specific
manner as shown before invitro and in animal studies [2-
9].
The sequences of the antisense strands of the ODNs used
here were chosen on the basis of known siRNA sequences,
recently shown to significantly inhibit HSV replication
[10,11]. The structure, sequences, and target sites of the
ODNs are shown in figure 1B. ODN 5, 29, and 30 target
the mRNA of the E genes UL 5, UL 29, and UL 30 essential
for DNA synthesis [12]. UL 5 encodes a component of the
helicase/primase complex, UL 29 a single strand binding
protein and UL 30 the DNA polymerase. ODN 48 and 48
G target the mRNA of the LL gene UL 48, which encodes
the virion associated VP16 needed in progeny virions for
the transcriptional activation of IE genes in the next round
of infection [13]. As controls, we used different oligodeox-
ynucleotides without any sequence similarity to the HSV-
1 genome (figure 1C) or phosphate buffered saline (PBS).
The ODNs used were protected against nucleases by thio-
ate modifications of the three terminal nucleotides at each
end and in the T4 linker as described [6,14].
We have chosen African green monkey kidney (Vero) cells
and human embryonic lung fibroblast (MRC-5) to dem-
onstrate the effect of the ODNs on HSV type 1 (HSV-1)
replication in vitro. Both cell lines are permissive to HSV-
1 strain McIntyre infection. Vero cells are defective in
interferon production and HSV infections of monolayers
produce a clear plaque phenotype. The MRC-5 cells were
chosen to confirm the results in a primary human cell
line.
First, we screened for an antiviral effect in confluent Vero
cells. The media were replaced by Dulbecco's modified
Eagle Medium (DMEM) with 2% fetal calf serum (FCS)
containing a mixture of HSV-1 virions and ODNs for co-
application. The virus was introduced at a multiplicity of
infection (moi) of 0.001 and the final concentration of
ODNs was 2.5 μM. After 24 h the cell culture supernatants
were harvested and HSV DNA levels were determined by
quantitative PCR (qPCR) using primers and a probe tar-
geting the HSV-1 glycoprotein G [15]. The ODNs against
HSV-1 reduced the viral titer by 60 to 80% in comparison
to infected cells incubated with PBS (data not shown). To
confirm this result the supernatants from this experiment
were serially diluted and used to infect confluent Vero
cells for plaque assays (figure 2A). After 1 h of incubation
with the virus the cells were overlaid with DMEM contain-
ing 2% FCS and 0.4% noble agar and grown for 3 to 4
days at 37°C. After removal of the medium the cells were
washed with PBS and stained with 1% crystal violet in
20% ethanol. The ODNs against HSV-1 exhibited a signif-
icant reduction of the viral titer, whereas the observed
effect with the control ODN A was comparable to the
infected cells treated with PBS as negative control. We per-
formed several experiments with co-application under the
same conditions and measured the viral titer in cell cul-
ture supernatants by qPCR 24 h after co-application. The
result is summarized in figure 2B. A two-tailed Student's t-
test with unequal variance was used to perform statistical
analysis. The reduction of viral titers was statistically sig-
nificant for ODNs 5, 29, 30 and 48 G (p < 0.01 against
PBS), but not for ODN 48 and the control ODN A. The
HSV-1 DNA levels could be reduced by 75%, although
HSV replication was slightly reduced by the control ODN
A in comparison to cells that were infected without
ODNs.
In order to examine the effect in more detail, we per-
formed experiments in Vero and MRC-5 cells using trans-
fection reagents, in contrast to the above-mentioned
experiment. To establish the best conditions for transfec-
tion, we determined transfection rates for a fluorescein-
labelled ODN A with different transfection reagents in
Vero cells. The best transfection rates were achieved after
an overnight incubation with Lullaby or Dreamfect Gold
transfection reagents, which were consecutively used in
further experiments (data not shown). Then, we trans-
fected Vero cells with different concentrations of ODN 48
G and incubated the cells overnight, before they were sub-
sequently infected with a moi of 0.001. Cells treated with
the unspecific ODN S2 at a final concentration of 50 nM
or PBS served as controls. 24 h after the infection the HSV
DNA levels in cell culture supernatants were determined
by qPCR. The reduction of viral replication was dose
dependent with a plateau at a concentration of 50 nM (fig-
ure 2C). The control ODN S2 did not show a reduction of
viral titer at this concentration. The supernatants of the
cells treated with ODN 48 G at a concentration of 50 nM
and the cells treated with PBS were used for plaque assays.
A reduction of plaque forming units by 90% in compari-
son to cells treated with PBS was observed (figure 2D).
Transfection reagents thus allow a reduction of the ODN
concentrations. Further transfection studies were carried
out with ODNs at 50 nM concentrations. Figure 3A dis-
plays a summary of all experiments with transfection of
ODNs into Vero cells and subsequent infection after 12 h.
The control oligonucleotides, single-stranded asS2, and
scrambled ODN Sc were tested additionally to ODN S2 to
investigate the sequence specifity of the observed effects.
Only ODN Sc showed a slight reduction of the HSV-1
DNA levels, but this effect was not significant. ODN 5
reduced the HSV-1 DNA levels significantly by 70% (p <
0.01) and ODN 48 G by 60% (p < 0.01). The ODNs 29,Virology Journal 2009, 6:43 http://www.virologyj.com/content/6/1/43
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Inhibition of HSV-1 by ODNs Figure 2
Inhibition of HSV-1 by ODNs. A and B. Co-application of ODNs and HSV-1. HSV-1 virions were mixed with 2.5 μM of the 
indicated ODNs, a concentration needed in the absence of transfection reagent. The mixture was added to Vero cells (arrow 
head and bold arrow with overline). The titer of HSV-1 was determined after 24 h. A. Plaque assay. The supernatants of 
infected cultures were assayed for plaque formation on Vero cells. Representative 1:100 dilutions of triplicates are shown. B. 
Quantitative PCR. HSV-1 DNA was purified from supernatants and quantified by glycoprotein G-specific PCR. Relative HSV-1 
DNA levels are shown +SE. The total number of infections (n) for each ODN is indicated below the graph. The statistical sig-
nificance is indicated by asterisks, **P ≤ 0.01 against PBS. C. Vero cells were treated with various concentrations of ODN 48 G 
and S2 as indicated in the presence of transfection reagent (indicated by circle) at the indicated concentrations and were incu-
bated over night (o/n) at 37°C. The cells were infected (bold vertical arrow) at a moi = 0.001 and after 24 h the HSV-1 DNA 
levels in the supernatants were measured by quantitative PCR (vertical arrow). The mean value ± SE of 2 different experiments 
is shown. D. Plaque Assay. Vero cells were transfected with 50 nM ODN 48 G or phosphate-buffered saline (PBS) and infected 
as described in A. Dilutions of the supernatant were assayed for plaque formation on Vero cells. Representative pictures of 
triplicates are shown. *P ≤ 0.05 against PBS.
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Analysis of ODN-mediated reduction of HSV-1 titer in Vero cells and primary lung fibroblasts Figure 3
Analysis of ODN-mediated reduction of HSV-1 titer in Vero cells and primary lung fibroblasts. A, B and C. Trans-
fection of ODNs. Vero cells (A, C) and primary lung fibroblasts (B, MRC-5 cells) were treated with 50 nM of the indicated 
ODNs or PBS for 5 to 16 h in the presence of transfection reagent. The medium was changed to DMEM and cells were incu-
bated for 1 h. The cells were infected and after 24 h the HSV-1 DNA levels in the supernatants were determined by quantita-
tive PCR. The mean value of all experiments +SE is shown. The total number of infections performed (n) is indicated below the 
graph. **P ≤ 0.01, *P ≤ 0.05 against PBS. C. Comparison of ODN 5 and siRNA UL5.2 targeting the same region of UL5 mRNA, 
performed as described in A. As negative control the commercially available siRNA siGLO RISC-Free (Dharmacon) was used.
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Table 1: Reduction of HSV-1 DNA levels upon treatment with ODNs in Vero and MRC-5 cells.
Treatment Average fold reduction of the mean (median)
Co-application Transfection with subsequent infection
Vero Vero MRC-5
PBS 1.0 (1.0) 1.0 (1.0) 1.0 (1.0)
Control 1.4 (1.4) 1.0 (1.0) 1.1 (1.1)
ODN 5 3.3 (6.5) 3.0 (5.0) 2.5 (2.2)
ODN 29 3.9 (4.1) 1.8 (1.3) 1.6 (2.4)
ODN 30 4.1 (4.1) 0.7 (1.3) 1.5 (1.6)
ODN 48 2.2 (3.1) 1.4 (1.7) n. d.
ODN48G 2.9 (3.6) 2.4 (2.4) 1.9 (2.0)
The data of all in vitro experiments are summarized. The average fold reductions of the mean and the median are shown (n. d., not determined).Virology Journal 2009, 6:43 http://www.virologyj.com/content/6/1/43
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30 and 48 did not show a significant reduction of the titer.
A cytotoxic effect of the ODNs was not observed as
revealed by proliferation assays (data not shown).
To examine whether the effect is reproducible in other cell
lines such as a primary human cell-line, we transfected
MRC-5 cells with the ODNs at a final concentration of 50
nM. The cells were infected 5 h post transfection at a moi
of 0.001 for 1 h and the viral titer was assayed 24 h after
infection by qRT-PCR. HSV-1 replication was only
impaired in cells treated with the HSV-specific ODNs (fig-
ure 3B). The controls ODN Cont and asS2 were negative.
The effect was statistically significant for ODN 5, 30 and
48 G. The ODNs did not exhibit a cytotoxic effect in MRC-
5 cells (data not shown). A direct comparison between
ODN5 and an siRNA is shown for Vero cells in figure 3C.
Table 1 summarizes all experiments listed under the dif-
ferent conditions. Overall, ODN 5, targeting a component
of the helicase/primase complex, has the greatest poten-
tial to inhibit HSV-1 replication in vitro, which is consist-
ent with reports about the helicase/primase complex
being a target for inhibiting the HSV-1 replication by
siRNA [10] (see figure 3C) and antiviral compounds
[16,17].
Antisense ODNs and small interfering RNAs are estab-
lished antiviral agents that have been shown to reduce
HSV replication [10,11,18]. Here we are demonstrating
that a new class of oligodeoxynucleotides – partially dou-
ble-stranded hairpin loop-structured ODNs with one
strand completely complementary to the target mRNA –
can reduce HSV-1 replication in vitro. The result is consist-
ent with previous studies reporting that hairpin loop-
structured ODNs have an antiviral effect on HIV-1 and
Influenza virus [2-9,19]. The modes of action of the
ODNs used in this study may be due to steric hindrance of
ribosomes and hybridization to the corresponding mRNA
thereby creating a substrate for cellular RNases H, compa-
rable to the modes of action of single-stranded ODNs
[20]. In a direct comparison with siRNAs and ODNs in
Vero cells both oligonucleotides were differentially effec-
tive, e.g. the most effective ODN 5 in this study was 2.5-
fold more effective than the corresponding siRNA-UL5.2
[10] (figure 3C), whereas ODN 29 was 2-fold less effective
than its analog (data not shown). This suggests that differ-
ent target sites might have preferences for particular types
of oligonucleotides. Furthermore, the second strand
linked to the antisense strand can modulate the effect in a
positive or negative manner by affecting stability, accessi-
bility, localization or uptake of the ODN. Overall, this
study underlines the potential of partially double-
stranded hairpin loop-structured ODNs as antiviral
agents.
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